Last 86.50 INR
Change Today +1.75 / 2.06%
Volume 205.7K
SAPH On Other Exchanges
Symbol
Exchange
Natl India
As of 4:05 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

shasun pharmaceuticals ltd (SAPH) Snapshot

Open
85.60
Previous Close
84.75
Day High
87.50
Day Low
84.30
52 Week High
11/7/13 - 94.20
52 Week Low
06/26/13 - 45.50
Market Cap
4.9B
Average Volume 10 Days
914.7K
EPS TTM
9.61
Shares Outstanding
56.6M
EX-Date
07/23/13
P/E TM
9.0x
Dividend
1.50
Dividend Yield
1.73%
Current Stock Chart for SHASUN PHARMACEUTICALS LTD (SAPH)

Related News

No related news articles were found.

shasun pharmaceuticals ltd (SAPH) Related Businessweek News

No Related Businessweek News Found

shasun pharmaceuticals ltd (SAPH) Details

Shasun Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and enteric coating excipients. The company offers API products in the areas of pain management, anti ulcerants, and CNS, such as Levetiracetan, Ibuprofen, Ranitidine base, Nizatidine, Methohexital, Isradipine, Gabapentin, Sulphazine, HPMCP, Olanzapine, Meprobamate, Quinapril, Cycloserine, Venlafaxine HCI, Sevelamer HCI, Sevelamer carbonate, Carisoprodol, and Ketoprofen. It also engages in contract research and manufacturing services business, which provides chemistry and analytical services; and offers formulation development and manufacturing services for solid dosage products to pharmaceutical customers. In addition, the company is involved in the creation of biotechnology capabilities and capacities in the area of protein processing solutions to provide services for the biotech and pharmaceutical companies. It exports its products to North America, Europe, Asia, and Latin America. The company was formerly known as Shasun Chemicals and Drugs Ltd. Shasun Pharmaceuticals Limited was founded in 1976 and is headquartered in Chennai, India.

Founded in 1976

shasun pharmaceuticals ltd (SAPH) Top Compensated Officers

Managing Director, Wholetime Director and Mem...
Total Annual Compensation: 8.4M
Wholetime Director and Member of Audit Commit...
Total Annual Compensation: 5.7M
Whole-Time Director
Total Annual Compensation: 5.7M
Director of Environment Health & Safety (EHS)...
Total Annual Compensation: 5.1M
Compensation as of Fiscal Year 2013.

shasun pharmaceuticals ltd (SAPH) Key Developments

Shasun Pharmaceuticals Ltd Enters into Joint Venture Agreement with SeQuent Scientific Limited

On July 13, 2013, Shasun Pharmaceuticals Ltd. announced the execution of a Letter of Intent to form a new Joint Venture with SeQuent Scientific Limited, Shasun Pharmaceuticals Ltd. announced that it has signed the Joint Venture Agreement on March 07, 2014 with SeQuent. The JV Company has been formed to develop, manufacture and sell veterinary products including both API and formulations to cater to the global market. In line with the Joint Venture Agreement, company has also executed on March 07, 2014 a Slump Sale Agreement transferring its Vizag facility to JV Company. SeQuent and Shasun will hold 73% and 27% respectively in the JV company. JV company is expected to be operational in the first quarter of 2014-15, subject to the customary closing conditions.

Shasun Pharmaceuticals Ltd. Reports Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Shasun Pharmaceuticals Ltd. reported consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, on consolidated basis, the company reported total income from operations (net) of INR 3,252.8 million compared to INR 2,707.6 million, profit from operations before other income, finance costs and exceptional items of INR 232.8 million compared to INR 81.3 million, profit from ordinary activities before tax of INR 129.6 million compared to INR 64.3 million and net profit of INR 130.4 million or INR 2.30 per basic and diluted share compared to INR 82.1 million or INR 1.45 per diluted share for the last year. For the nine months, on consolidated basis, the company reported total income from operations (net) of INR 8,494.3 million compared to INR 8,084.4 million, profit from operations before other income, finance costs and exceptional items of INR 238.3 million compared to INR 562.5 million, profit from ordinary activities before tax of INR 95.1 million compared to INR 415.6 million and net profit of INR 198.1 million or INR 3.50 per basic and diluted share compared to INR 397.8 million or INR 7.02 per diluted share for the last year. For the quarter, on standalone basis, the company reported total income from operations (net) of INR 2,465.4 million compared to INR 1,970.7 million, profit from operations before other income, finance costs and exceptional items of INR 178.9 million compared to INR 9.8 million, profit from ordinary activities before tax of INR 100.5 million compared to INR 11.1 million and net profit of INR 101.2 million or INR 1.79 per basic and diluted share compared to INR 28.9 million or INR 1.51 per diluted share for the last year. For the nine months, on standalone basis, the company reported total income from operations (net) of INR 6,457.3 million compared to INR 5,737.5 million, profit from operations before other income, finance costs and exceptional items of INR 337.4 million compared to INR 268.4 million, profit from ordinary activities before tax of INR 138.7 million compared to INR 177.8 million and net profit of INR 241.7 million or INR 4.27 per basic and diluted share compared to INR 160.0 million or INR 2.83 per diluted share for the last year.

Shasun Pharmaceuticals Ltd - Shareholder/Analyst Call

Shasun Pharmaceuticals Ltd - Shareholder/Analyst Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAPH:IN 86.50 INR +1.75

SAPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 552.30 INR +4.50
Dishman Pharmaceuticals & Chemicals Ltd 88.95 INR +0.60
Divi's Laboratories Ltd 1,322 INR -2.55
Jubilant Life Sciences Ltd 169.50 INR -1.50
Piramal Enterprises Ltd 601.45 INR +3.90
View Industry Companies
 

Industry Analysis

SAPH

Industry Average

Valuation SAPH Industry Range
Price/Earnings 15.4x
Price/Sales 0.4x
Price/Book 1.8x
Price/Cash Flow 5.6x
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHASUN PHARMACEUTICALS LTD, please visit www.shasun.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.